Checkpoint Therapeutics Inc (CKPT)

$2.67

-0.01

(-0.37%)

Market is closed - opens 7 PM, 18 Jul 2024

Performance

  • $2.56
    $2.76
    $2.67
    downward going graph

    4.12%

    Downside

    Day's Volatility :7.24%

    Upside

    3.25%

    downward going graph
  • $1.30
    $3.62
    $2.67
    downward going graph

    51.31%

    Downside

    52 Weeks Volatility :64.09%

    Upside

    26.24%

    downward going graph

Returns

PeriodCheckpoint Therapeutics IncIndex (Russel 2000)
3 Months
66.87%
0.0%
6 Months
46.7%
0.0%
1 Year
-16.04%
0.0%
3 Years
-90.63%
-18.2%

Highlights

Market Capitalization
98.6M
Book Value
- $0.29
Earnings Per Share (EPS)
-2.61
PEG Ratio
0.0
Wall Street Target Price
21.67
Profit Margin
0.0%
Operating Margin TTM
-66195.59%
Return On Assets TTM
-314.85%
Return On Equity TTM
-1220.38%
Revenue TTM
68.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-91.9%
Gross Profit TTM
-48.2M
Diluted Eps TTM
-2.61
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.24
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
-0.27
EPS Estimate Next Quarter
-0.27

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Checkpoint Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 711.61%

Current $2.67
Target $21.67

Technicals Summary

Sell

Neutral

Buy

Checkpoint Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Checkpoint Therapeutics Inc
Checkpoint Therapeutics Inc
37.63%
46.7%
-16.04%
-90.63%
-90.57%
Moderna, Inc.
Moderna, Inc.
-6.91%
25.22%
1.18%
-60.44%
769.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
4.48%
16.73%
49.42%
85.5%
258.18%
Novo Nordisk A/s
Novo Nordisk A/s
-3.82%
25.91%
69.01%
206.62%
460.98%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.51%
12.79%
36.04%
145.12%
174.23%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Checkpoint Therapeutics Inc
Checkpoint Therapeutics Inc
NA
NA
0.0
-1.24
-12.2
-3.15
NA
-0.29
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.36
32.36
1.46
44.28
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.58
48.58
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.75
31.75
0.53
17.06
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Checkpoint Therapeutics Inc
Checkpoint Therapeutics Inc
Buy
$98.6M
-90.57%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
769.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$120.7B
258.18%
32.36
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.0B
460.98%
48.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.2B
174.23%
31.75
39.46%

Insights on Checkpoint Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 5 quarters, 74.0K → 6.0K (in $), with an average decrease of 36.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -19.12M → -10.94M (in $), with an average increase of 74.8% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 69.0% return, outperforming this stock by 85.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 205.5% return, outperforming this stock by 295.8%

Institutional Holdings

  • Armistice Capital, LLC

    7.61%
  • Vanguard Group Inc

    2.57%
  • Renaissance Technologies Corp

    0.76%
  • Geode Capital Management, LLC

    0.56%
  • BlackRock Inc

    0.46%
  • Advisor Group Holdings, Inc.

    0.38%

Company Information

checkpoint therapeutics, inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. the company's product candidates include ck-101 that in phase i clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and cosibelimab, a programmed death ligand-1 (pd-l1), which is in phase i clinical trial in patients with selected recurrent or metastatic cancers. it also develops ck-103, a small molecule inhibitor of bet bromodomains; and ck-302, a human agonistic antibody for oncology indications. checkpoint therapeutics, inc. has collaboration agreements with tg therapeutics, inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. the company was founded in 2014 and is headquartered in new york, new york. checkpoint therapeutics, inc. is a subsidiary of fortr

Organization
Checkpoint Therapeutics Inc
Employees
23
CEO
Mr. James F. Oliviero III, C.F.A.
Industry
Health Technology

FAQs